Dr. Grosh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5910 Mechunk Ridge lane
Keswick, VA 22947Phone+1 434-296-5593Fax+1 434-296-4399
Education & Training
Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 1980 - 1982- Vanderbilt University Medical CenterResidency, Internal Medicine, 1974 - 1977
Columbia University Vagelos College of Physicians and SurgeonsClass of 1974
Certifications & Licensure
VA State Medical License 1988 - 2026
TN State Medical License 1980 - 1988
WI State Medical License 1977 - 1979- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2005 Jul 01
- Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer Start of enrollment: 2018 Oct 29
Publications & Presentations
PubMed
- 9 citationsPhase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64).Rick Daniel Vavolizza, Gina R Petroni, Ileana S Mauldin, Kimberly A Chianese-Bullock, Walter C Olson
Journal for Immunotherapy of Cancer. 2022-09-01 - 10 citationsImmunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.Max O. Meneveau, Gina R. Petroni, Elise P. Salerno, Kevin T. Lynch, Mark E. Smolkin
Journal for Immunotherapy of Cancer. 2021-05-01 - 16 citationsTrial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63).Craig L. Slingluff, Gina R. Petroni, Kimberly A. Chianese-Bullock, Nolan A. Wages, Walter C. Olson
Journal for Immunotherapy of Cancer. 2021-01-01
Grant Support
- Evalof Immune Status Following The Administration Of Chemotherapy Or SteroidsNational Center For Research Resources2009
- Evalof Immune Status Following The Administration Of Chemotherapy Or SteriodsNational Center For Research Resources2008
- Taxol In Refractory Ovarian CancerNational Center For Research Resources1993
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
